Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998755 | 0.86 | APP (0.44) | GRM5ALOX5APCNR2 | |
| SCHEMBL13248358 | 0.81 | ALOX5AP (0.53) | ALOX5APCYP19A1MAOBNR1H4FFAR1 | |
| SCHEMBL26123199 | 0.77 | GRM5 (0.47) | GRM5CYP19A1RORCMAOB | |
| SCHEMBL31399246 | 0.77 | GRM5 (0.47) | GRM5CYP19A1RORCMAOB | |
| SCHEMBL3000768 | 0.77 | MAOB (0.43) | ALOX5APCYP19A1MAOBNR1H4FFAR1 | |
| SCHEMBL707618 | 0.75 | ALOX5AP (0.62) | ALOX5APCYP19A1MAOBFFAR1 | |
| SCHEMBL480209 | 0.73 | ALOX5AP (0.63) | ALOX5APCYP19A1MAOBFFAR1 | |
| SCHEMBL30468703 | 0.73 | KIF11 (0.55) | CYP19A1 | |
| SCHEMBL3000188 | 0.73 | ACACB (0.46) | ALOX5APCYP19A1MAOBNR1H4FFAR1 | |
| SCHEMBL24301598 | 0.71 | GRM5 (0.38) | GRM5CYP19A1MAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | GPBAR1 295/4885GRM5 1574/4885ALOX5AP 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.